Literature DB >> 2473126

Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling.

I Seppälä1, O Mäkelä.   

Abstract

Protein conjugates of polysaccharides or their breakdown products are being used as improved "T-dependent" vaccines. We tried to define optimal characteristics of future conjugate vaccines by testing the immunogenicity of thirteen conjugates of alpha 1-6 dextran and chicken serum albumin in mice (BALB/c and CBA). All conjugates induced stronger antidextran antibody responses than the polysaccharide, and a fair proportion of these antibodies were IgG. However, there was a range of antigenicities. Consistently strong responses were obtained with conjugates that carried small dextran molecules (m.w. 1000 to 4000) coupled to the protein via the reducing end. Modification of such an "optimal" conjugate either by increasing the size of the saccharide to 40,000 Da, or by permitting multiple attachments of the saccharide molecule to the protein, reduced its antigenicity. Carbohydrate/protein ratios varying from 0.17 to 0.49 were associated with excellent antidextran responses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473126

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Efficient solid-phase synthesis of meningococcal capsular oligosaccharides enables simple and fast chemoenzymatic vaccine production.

Authors:  Timm Fiebig; Christa Litschko; Friedrich Freiberger; Andrea Bethe; Monika Berger; Rita Gerardy-Schahn
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

2.  Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.

Authors:  L C Paoletti; D L Kasper; F Michon; J DiFabio; H J Jennings; T D Tosteson; M R Wessels
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

3.  Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.

Authors:  Francis Michon; Catherine Uitz; Arun Sarkar; Anello J D'Ambra; Maryline Laude-Sharp; Samuel Moore; Peter C Fusco
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

Authors:  M R Wessels; L C Paoletti; H K Guttormsen; F Michon; A J D'Ambra; D L Kasper
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  Immunogenicity of bacterial carbohydrates: cholera toxin modulates the immune response against dextran B512.

Authors:  E Sverremark; C Fernandez
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

6.  Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae.

Authors:  T H Wu; X X Gu
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

7.  Unresponsiveness following immunization with the T-cell-independent antigen dextran B512. Can it be abrogated?

Authors:  E Sverremark; C Fernandez
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

8.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

9.  Understanding thymus-independent antigen-induced reduction of thymus-dependent immune responses.

Authors:  Karin Lindroth; Elena Fernández Mastache; Izaura Roos; Africa González Fernández; Carmen Fernández
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

10.  Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.

Authors:  Francesca Micoli; Maria Rosaria Romano; Marta Tontini; Emilia Cappelletti; Massimiliano Gavini; Daniela Proietti; Simona Rondini; Erwin Swennen; Laura Santini; Sara Filippini; Cristiana Balocchi; Roberto Adamo; Gerd Pluschke; Gunnstein Norheim; Andrew Pollard; Allan Saul; Rino Rappuoli; Calman A MacLennan; Francesco Berti; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.